文献速递母胎医学产科

胎儿水肿微阵列结果非诊断性后基于测序的基因检测临床效用:基于人群的队列研究

The Clinical Utility of Sequence-Based Genetic Testing for Fetal Edema Following Non-Diagnostic Microarray Results: A Population-Based Cohort Study.
PubMed 文献 · Prenat Diagn · 2026-03-03

该研究在114例胎儿水肿且微阵列结果非诊断性的病例中评估测序的诊断率。经多学科评估后51例(54%)接受靶向基因、基因panel和/或外显子测序,17例(34%)确诊,其中59%提供≥25%的复发风险。RASopathy检测和外显子测序诊断率分别为18.5%和41.2%。

要点

  • 微阵列非诊断性胎儿水肿病例中,测序总诊断率为34%(17/114),确诊者59%复发风险≥25%。
  • RASopathy panel测序诊断率18.5%,外显子测序诊断率41.2%,后者采用选择性标准。
  • 颈项透明层增厚或囊性水瘤病例推荐RASopathy panel测序与CMA同时作为标准诊疗。

核心结论

  • 在微阵列结果非诊断性的胎儿水肿病例中,进一步测序可提供诊断信息,尤其对颈项透明层增厚或囊性水瘤病例,RASopathy panel测序诊断率良好,应作为标准诊疗与CMA一同提供。

研究设计与样本

  • 基于人群的队列研究,纳入2014-2022年因胎儿水肿转诊进行基因检测的病例,共114例微阵列结果非诊断性。

主要发现

  • 多学科审查在79例(83%)中进行,51例(54%)基于临床评估接受了靶向基因、基因panel和/或外显子测序。
  • 17例(34%)获得诊断,其中59%提供≥25%的复发风险。
  • RASopathy检测的诊断率为18.5%,外显子测序(采用选择性标准)的诊断率为41.2%。
  • 最高诊断率见于胎儿水肿和其他类型胎儿水肿(局限于一个体腔)的病例。

关键数值与推荐

  • 胎儿水肿定义包括颈项透明层>3.5 mm、囊性水瘤、水肿及其他类型。
  • RASopathy panel测序诊断率18.5%,外显子测序诊断率41.2%。
  • 确诊者中59%提供≥25%的复发风险。

临床怎么用

  • 对微阵列结果非诊断性的胎儿水肿病例,尤其颈项透明层增厚或囊性水瘤,应提供RASopathy panel测序与CMA作为标准诊疗。
  • 结合新出现的产前和产后发现及多学科团队审查,可指导额外检测、咨询和妊娠管理选择。
  • 非免疫性胎儿水肿病例尤其需要考虑多学科评估和进一步测序。

局限性

  • 研究未评估测序的总体诊断率,而是采用选择性方法对部分病例进行额外检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ultrasound findings of fetal edema may provide early evidence of a genetic disorder. Our objective was to evaluate the frequency and diagnostic yield of sequencing in a selected population after a non-diagnostic microarray result for fetal edema. METHOD: Fetal edema (nuchal translucency > 3.5 mm, cystic hygroma, hydrops, other types) cases referred for genetic testing (2014-2022) were identified in our laboratory information system. Chart review confirmed associated ultrasound findings, findings from other imaging or pathology, multidisciplinary review, and genetic test utilization. Descriptive analyses determined diagnostic yields. RESULTS: There were 114 fetal edema cases with a non-diagnostic microarray result. Multidisciplinary review occurred in 79 (83%) cases, with targeted genes, gene panels, and/or exomes performed in 51 (54%) cases based on clinical assessment. Diagnoses were made in 17 (34%, with 59% providing a recurrence risk of ≥ 25%). RASopathy testing and exomes (with selective criteria) resulted in diagnostic yields of 18.5% and 41.2%, respectively. The highest diagnostic yields were in cases with fetal hydrops and other types of fetal edema (restricted to one body cavity). CONCLUSION: Review of additional testing beyond CMA in this cohort did not attempt to assess the overall yield of sequencing; instead, the study used a selected approach in which cases of fetal edema underwent further testing beyond CMA. In cases with cystic hygroma or increased nuchal translucency, RASopathy panel sequencing provides a good diagnostic yield, and should be offered as standard of care with CMA. Correlation of new and developing prenatal and postnatal findings, along with multidisciplinary team review, may inform additional testing, counseling and pregnancy management options, and is particularly important to consider in cases presenting with non-immune fetal hydrops.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Allen VM, Arts HH, Schollenberg E, et al. The Clinical Utility of Sequence-Based Genetic Testing for Fetal Edema Following Non-Diagnostic Microarray Results: A Population-Based Cohort Study. Prenat Diagn. 2026. PMID: 41775679. doi:10.1002/pd.70116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。